Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15222067 | 1.00 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL18374424 | 1.00 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL24104956 | 0.98 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL8225093 | 0.95 | — | — | |
| SCHEMBL13201852 | 0.95 | — | — | |
| SCHEMBL25846167 | 0.95 | — | — | |
| SCHEMBL13201869 | 0.95 | — | — | |
| SCHEMBL24105302 | 0.95 | — | — | |
| SCHEMBL18649194 | 0.95 | — | — | |
| SCHEMBL21159481 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018121678-A1 | PRODRUG OF ANTIVIRAL NUCLEOSIDE ANALOGUES, AND COMPOSITION AND USE THEREOF | 广东东阳光药业有限公司 | 2018-07-05 | — | — | WO | disclosed |
| US-9833440-B2 | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170157096-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | ACHILLION PHARMACEUTICALS, INC. | 2017-06-08 | — | — | US | disclosed |
| WO-2017076201-A1 | HCV INHIBITORS, PREPARATION METHOD AND USE THEREOF | 江苏豪森药业集团有限公司 | 2017-05-11 | — | — | WO | disclosed |
| WO-2017076187-A1 | 1,4(1,4)-DIPHENYLHEXACYCLOPHANE-12,43-DIYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 | 2017-05-11 | — | — | WO | disclosed |
| US-9592222-B2 | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9474742-B2 | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9468629-B2 | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160113907-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | ACHILLION PHARMACEUTICALS, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160115157-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | ACHILLION PHARMACEUTICALS, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9273082-B2 | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20140323458-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | ACHILLION PHARMACEUTICALS, INC. | 2014-10-30 | — | — | US | disclosed |
| EP-2044010-B1 | NEW PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INIHIBITORS AND THE USE THEREOF | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDO RESZVENYTARSASAG (HU) | 2014-01-08 | — | — | EP | disclosed |
| US-8426359-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-7960558-B2 | Pharmaceutical intermediate for synthesizing ACE inhibitors and the use thereof | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2011-06-14 | — | — | US | disclosed |
| US-7960558-B2 | Pharmaceutical intermediate for synthesizing ACE inhibitors and the use thereof | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2011-06-14 | — | — | US | disclosed |
| US-20100286404-A1 | PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INHIBITORS AND THE USE THEREOF | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-11-11 | — | — | US | disclosed |
| US-20100286404-A1 | PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INHIBITORS AND THE USE THEREOF | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-11-11 | — | — | US | disclosed |
| WO-2007132277-A1 | NEW PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE- INHIBITORS AND THE USE THEREOF | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság (HU) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286404-A1 | PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INHIBITORS AND THE USE THEREOF | ACE, AGTR1, REN | ALDH1A1 287/4885 |
| US-20160113907-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | HAVCR2, HCCS, AHR | ALDH1A1 92/4885 |
| US-20160115157-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | HAVCR2, HCCS, AHR | ALDH1A1 92/4885 |
| US-20140323458-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | HAVCR2, HCCS, AHR | ALDH1A1 92/4885 |
| US-20170157096-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | HAVCR2, HCCS, AHR | ALDH1A1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.